“Bimekizumab Efficacy and Safety versus Adalimumab in Patients with Moderate to Severe Plaque Psoriasis: Results from a Multicenter, Randomized, Double-Blinded Active Comparator-Controlled Phase 3 Trial (BE SURE)”, J of Skin, vol. 5, no. 1, p. s15, Jan. 2021, doi: 10.25251/skin.5.supp.15.